Vaxcyte Inc. Common Stock vs State Street SPDR S&P Homebuilders ETF — how do they compare? Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B), while State Street SPDR S&P Homebuilders ETF trades at $92.84 (market cap $1.49B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 7.1× State Street SPDR S&P Homebuilders ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and State Street SPDR S&P Homebuilders ETF for 35 Days on average.
| PCVX | XHB | |
|---|---|---|
Market Cap | $10.51B | $1.49B |
Volume | 2,644,694 | 1,578,908 |
Sector | Health | Broad Market / Factor |
52-Week High | $73.82 | $121.36 |
52-Week Low | $40.32 | $92.84 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $9.14B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.70, up 0.69% on the day, but technical indicators signal a bearish trend with moving averages and overall momentum pointing lower. Recent news highlights mixed housing data, with rising mortgage rates pressuring the sector but new legislation and institutional interest offering potential support. The ETF lacks current fundamental ratio data but tracks homebuilder stocks sensitive to economic cycles.
The outlook for XHB hinges on housing market dynamics; opportunities exist if affordability improves or construction accelerates, but risks include persistent high rates and economic slowdowns. Investor sentiment is cautious amid volatile home sales data, requiring close watch on macroeconomic indicators for directional clarity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →